STAT+: GLP-1 reduced migraine frequency by nearly half, in a pilot study
Researchers say GLP-1 agonists significantly reduced migraine frequency in participants who were obese.
GLP-1 drugs could treat more than just diabetes and obesity. They may also reduce migraine frequency.
That is according to the findings of a study presented on Friday at the European Academy of Neurology congress. The pilot study found that GLP-1 agonists reduced monthly migraine days by almost half. The authors hypothesized that the drug lowers migraine frequency by reducing intracranial pressure.
“It’s a hugely interesting and very important study, and it opens all sorts of questions about how the drug works,” said Alexandra Sinclair, chair of the neurology department at the University of Birmingham. She was not involved in the study but has previously researched the agonists’ role in reducing intracranial pressure.
